MyAverix Finance MyAverix Finance

US

Prostatype Genomics AB (publ) (PGABF)

Prostatype Genomics AB (publ) (PGABF) is listed on US. As of 2026-03-30, reported P/E ratio is 18.00, net margin is 0.0%. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-30

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for PGABF

P/E ratio
18.00
Gross profit (TTM)
$0
Net margin
0.0%

Prostatype Genomics AB (publ) (PGABF) — FAQ

What is PGABF's P/E ratio?

The price-to-earnings (P/E) ratio for Prostatype Genomics AB (publ) (PGABF) is 18.00 (data as of 2026-03-30).

Does Prostatype Genomics AB (publ) pay a dividend?

Dividend yield is not available in the current snapshot for Prostatype Genomics AB (publ) (PGABF). Check the MyAverix Finance app for the latest dividend data.

What exchange is PGABF listed on?

PGABF is listed on US.

What is Prostatype Genomics AB (publ)'s net margin?

Prostatype Genomics AB (publ) (PGABF) reports a net margin of 0.0% (data as of 2026-03-30).

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play